



Biotech Daily

Tuesday July 1, 2014

Daily news on ASX-listed biotechnology companies

- * **JUNE BDI-40 UP 0.4%, YTD UP 0.3%; 8-YEARS UP 130%, ASX200 6%**
 - **YTD: BENITEC UP 780%, ANTEO UP 291%, ACRUX DOWN 72%**
- * **TODAY: ASX DOWN, BIOTECH UP: IDT UP 10%, ANALYTICA DOWN 7%**
- * **PSIVIDA ADDS 10 MORE EU COUNTRIES TO ILUVIEN APPROVAL**
- * **SIMAVITA CLAIMS FIRST US SALES**
- * **REGAL UNDERWRITES \$1.4m IN EXPIRING SUDA OPTIONS**
- * **LOU PANACCIO STARTS AS AVITA CHAIRMAN, DALTON GOODING GOES**
- * **BLUECHIIP: DR JASON CHAFFEY M-D; JOE BAINI, RON FINKEL TO GO**

MARKET REPORT

The Australian stock market fell 0.37 percent on Tuesday July 1, 2014 with the S&P ASX 200 down 19.8 points to 5,375.9 points.

Eighteen of the Biotech Daily Top 40 stocks were up, nine fell, nine traded unchanged and four were untraded.

IDT was the best, up two cents or 10.0 percent to 22 cents with 30,000 shares traded.

Both Pharmaxis and Prana climbed 9.1 percent; Ellex was up 6.7 percent; Anteo, Avita and Phosphagenics were up five percent or more; Bionomics, Cellmid and Patrys climbed more than three percent; Acrux, Alchemia, Genetic Technologies, Impedimed, Medical Developments, Mesoblast and Prima rose two percent or more; with CSL and Sirtex up by less than one percent.

Analytica led the falls, down 0.3 cents or 7.0 percent to four cents with 2.2 million shares traded, followed by Osprey down 6.25 percent to 52.5 cents with 44,850 shares traded.

Resmed and Tissue Therapies lost more than three percent; Atcor, Living Cell, Nanosonics and Neuren fell more than one percent; with Benitec, Cochlear and Starpharma down by less than one percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

The Biotech Daily Top-40 Index (BDI-40) rose 0.4 percent in June, compared to the ASX200 down 1.8 percent, with significant improvements balanced by many small falls.

The sector fell 2.9 percent for the year to June 30, 2014, compared to the S&P ASX200 climbing 12.3 percent for the 12 months, but the eight year data from the inception of the index tells a very different story.

Since June 30, 2006, the ASX200 was up just 6.3 percent, while the comparable value of Biotech Daily Top 40 stocks climbed 129.8 percent from a cumulative market capitalization of \$3,563 million in 2006 to an adjusted value of \$8,188 million at last night's close. The latter figure includes the value of the eight companies acquired in that period, a similar methodology to the ASX200.

For the year to June 30, 2014, Benitec was the best, up 780 percent to a market capitalization of \$132 million, followed by Anteo (291.1%), Admedus (275%), Tissue Therapies (212.0%), Impedimed (158.8%), Viralytics (138.1%) and Ellex (135.3%).

The financial year's worst performers were the demoted QRX which lost 91.7 percent of its value from \$156 million to \$13 million and Reva down 74.7 percent to \$47 million.

Inside the BDI-40, the worst for the year was Acrux, down 71.6 percent to \$167 million, followed by Universal Biosensors (70.3%), Optiscan (54.5%), Pharmaxis (53.5%) and Genetic Technologies (48.8%).

The three Big Caps (which are not included in the BDI-40) were up a cumulative 3.5 percent for the year to date, but down 4.4 percent for the month of June, with a 6.6 percent fall by CSL overshadowing Cochlear up 2.7 percent and Resmed up 1.9 percent.

In the month of June, 17 of the BDI-40 companies were up, 21 fell and two were unchanged.


Admedus was June's best, up 45.5 percent to \$195 million, followed by Bionomics up 36.1 percent for the month and 78.3 percent for the year to \$230 million, Compumedics up 33.3 percent for the month and 118.2 percent for the year to \$24 million, Neuren up 20.6 percent, Ellex (17.6%), GI Dynamics (16.0%) and Acrux, recovering 15.2 percent.

Prima had the deepest fall in June, down 29.0 percent to \$49 million, followed by Anteo retreating 22.5 percent from its all-time high to \$158 million, Circadian down 18.2 percent, both Optiscan and IDT down 16.7 percent, Patrys (12.5%) and Starpharma (12.2%).


Outside the BDI-40, Genera was June's best, up 55 percent to \$31 million and up 244.4 percent for the year, while OBJ retreated 5.5 percent for the month, but was up 830.8 percent for the year.

On the Nasdaq, Biota recovered 4.95 percent to \$106 million, Heartware slipped 3.1 percent to \$1,595 million and Sunshine Heart was up 2.0 percent to \$100 million.

BDI-40 (\$m) v S&P ASX 200 – Jun 30, 2013- Jun 30, 2014



BDI-40 v ASX200 Jun 30, 2006 to Jun 30, 2014 - Adjusted



[PSIVIDA](#)

Psivida says the European regulatory process for marketing authorizations has entered the national phase following the completion of the Mutual Recognition Procedure. Psivida said that Belgium, the Czech Republic, Denmark, Finland, Ireland, Luxembourg, the Netherlands, Norway, Poland and Sweden would grant a marketing authorization for Iluvien for vision impairment associated with chronic diabetic macular oedema considered insufficiently responsive to available therapies.

The company said that Iluvien initially received marketing authorizations in Austria, France, Italy, Portugal, Spain, the UK and Germany.

Psivida said that following authorization in the first European Union member state, the same authorization could be used to obtain marketing authorization in other member states not involved in the original, authorization.

Psivida chief executive officer Dr Paul Ashton said that “continuing to expand the countries where Iluvien can reach patients with this devastating disease is important and we look forward to the addition of these 10 countries”.

Psivida was untraded at \$4.23.

SIMAVITA

Simavita says its first order of its smart incontinence management (SIM) system is in use in the US, through its North American distributor Medline Industries.

Simavita said that the SIM Generation 4 was being used in long term care facilities in the States of Maryland, Washington and Illinois, with the purchase of SIM assessments from Medline, signalling the official beginning of US sales.

Simavita said that Medline launched the smart incontinence management product at the National Association Directors of Nursing Administration in Long Term Care meeting in Anaheim, California, from June 7 to 11, 2014.

The company said that it had 32 active Australian sites with supply agreements, all conducting SIM assessments and that an additional aged care group had signed a supply agreement, with deployment at its multiple sites planned for later in 2014.

The company said that monthly revenue had increased by more than 100 percent since February 2014.

Simavita said that its first site in Denmark was being constructed as a showcase in collaboration with the Municipality of Copenhagen and Abena A/S and would provide the platform for other potential distributors in Europe to view the technology operating in a Danish aged care facility.

Simavita was up four cents or 8.7 percent to 50 cents.

SUDA

Suda says that Regal Funds Management will underwrite unlisted five cent options which expired last night, June 30, 2014, returning about \$1.4 million to the company.

Suda said that the Sydney-based Regal Funds would earn a fee of four percent on the amount underwritten and the funds would be used on the further development of projects and provide working capital.

Suda was up 0.3 cents or six percent to 5.3 cents.

AVITA MEDICAL

Avita Medical says that Lou Panaccio has assumed the role of chairman and director Ian Macpherson has stepped down as interim chairman (BD: May 20, 2014).

Avita said that former chairman Dalton Gooding has resigned as a director after 12 years with the company.

The company said that Timothy Rooney continued as the interim chief executive officer as the board "considered it appropriate that the company's new chairman oversees any potential changes to the management structure".

Avita was up half a cent or five percent to 10.5 cents.

BLUECHIIP

Bluechiip says that acting chief executive officer Dr Jason Chaffey has been appointed managing director effective from today.

Bluechiip said Dr Chaffey was appointed acting chief executive officer, following the departure of founding chief executive officer Brett Schwarz (BD: Jan 28, 2014).

The company said that directors Joe Bains and Ron Finkel would resign as directors effective from August 1, 2014 and executive chairman Iain Kirkwood would revert to a non-executive role from today.

Bluechiip was untraded at 4.1 cents.

BIOTECH DAILY'S TOP 40 WITH MARKET CAPITALIZATION

Company \$Am	Jul-13	Jun-14	Jul-14
Cochlear	3,540	3,428	3,521
CSL	30,042	33,888	31,667
Resmed	7,843	7,548	7,688
BDI-20			
Acrux	589	145	167
Alchemia	104	162	180
Admedus	52	134	195
Benitec	15	138	132
Bionomics	129	169	230
Biotron	19	21	24
Clinuvel	72	65	72
GI Dynamics	171	237	275
Impedimed	17	48	44
Mesoblast	1,716	1,544	1,438
Nanosonics	157	203	208
Neuren	83	107	129
Osprey	46	62	69
Pharmaxis	43	20	20
Prima	80	69	49
Psivida	93	114	124
Sirtex	676	960	947
Tissue Therapies	25	76	78
Universal Biosensors	118	38	35
Viralytics	21	55	50
Second 20			
Analytica	11	34	35
Anteo	46	204	158
Antisense	14	21	20
Atcor	11	17	15
Avita	44	34	33
Cellmid	16	17	19
Circadian	11	11	9
Compumedics	11	18	24
Ellex	17	34	40
Genetic Technologies	43	24	22
IDT	11	18	15
Living Cell	15	20	18
Medical Developments	75	72	76
Oncosil	10	39	36
Optiscan	11	6	5
Patrys	11	24	21
Phosphagenics	133	93	89
Prana	92	108	108
Starpharma	233	188	165
Uscom	13	21	18

* Biotech Daily editor, David Langsam, owns shares in Acrux, Alchemia, Allied Health, Benitec, Biota, Mesoblast, Nanosonics, Neuren and non-biotechnology stocks. Through Australian Ethical Superannuation he has an indirect interest in Acrux, Alchemia, Atcor, Avita, Circadian, Cochlear, CSL, Ellex, IDT, Neuren, Pharmaxis, Prana, Resmed, Sirtex and Universal Biosensors. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily